Response to Inhaled Nitric Oxide and Mortality Among Very Preterm Neonates With Pulmonary Hypertension
Authors: Michelle Baczynski, Dany Weisz, Laura Thomas, Stephanie Fevrier, Michael Castaldo, Amuchou Soraisham, Abbas Hyderi, Rula Agarushi, Soume Bhattacharya, Renjini Lalitha, Amneet Sidhu, Muzafar Gani Abdul Wahab, Gabriel Altit, Audrey Hébert, Deepak Louis, Yasser Elsayed, Souvik Mitra, Poorva Deshpande, Ashraf Kharrat, Faith Zhu, Joseph Ting, Eugene Yoon, Prakesh S. Shah, Amish Jain, Carlos Fajardo, Jonathan Wong, Andrzej Kajetanowicz, Bruno Piedboeuf, Christine Drolet, Valerie Bertelle, Edith Masse, Anie Lapointe, Guillaume Ethier, Keith Barrington, Brigitte Lemyre, Hala Makary, Ahmad Aziz, Ayman Abou Mehrem, Amit Mukerji, Mary Seshia, Deepak Louis, Kyong-Soon Lee, Jehier Afifi, Jo-Anna Hudson, Victoria Bizgu, Nina Nouraeyen, Faiza Khurshid, Kevin Coughlin, Marie St-Hilaire, Marc Beltempo, Marco Zeid, Prakeshkumar Shah, Andrei Harabor, Jennifer Toye, Joseph Ting, Miroslav Stavel, Lannae Strueby, Gabriela Nunes, Wissam Alburaki, Ann Yi, Chelsea Ruth, Eugene Ng, Rebecca Sherlock, Paloma Costa, Thevanisha Pillay, Sajit Augustine
Journal: JAMA Network Open (2025)

Importance Clinical observations of immediate improvement in fraction of inspired oxygen (FiO 2 ) in a proportion of cases is often cited as the rationale for using inhaled nitric oxide (iNO) in the management of acute pulmonary hypertension among very preterm neonates (gestational age, &amp;amp;lt;32 weeks). However, the clinical effectiveness of such a response pattern remains underinvestigated. Objective To identify factors associated with predischarge mortality among very preterm neonates receiving iNO for acute pulmonary hypertension, with specific a priori emphasis on iNO responsiveness. Design, Setting, and Participants This prospective observational cohort study was conducted from January 1, 2018, to December 31, 2022, at 12 Canadian tertiary neonatal intensive care units. Consecutive very preterm neonates who received iNO for a diagnosis of acute pulmonary hypertension and pretreatment FiO 2 of 0.50 or more were included. Neonates with congenital anomalies or those who were treated for chronic pulmonary hypertension with iNO were excluded. Early acute pulmonary hypertension (≤72 hours of age) and late acute pulmonary hypertension (&amp;amp;gt;72 hours of age) cohorts were analyzed separately. Statistical analysis was performed from January 2023 to January 2024. Exposure Treatment with iNO for acute pulmonary hypertension. Main Outcomes and Measures The study cohorts were divided for comparison based on the primary outcome of predischarge mortality. Logistic regression analyses were used with predefined variables, including iNO responsiveness, to identify factors associated with mortality. A positive response to iNO was defined as a pre-iNO minus 4-hour post-iNO FiO 2 of 0.20 or more. Results The early acute pulmonary hypertension group (mean [SD] birth gestational age, 26.3 [2.4] weeks; median treatment age, 1 day [IQR, 1-2 days]; 147 boys [56%]) included 262 neonates; 179 (68%) had a pre-iNO FiO 2 of 1.0. The late acute pulmonary hypertension group (mean [SD] birth gestational age, 24.9 [1.7] weeks; median treatment age, 13 days [IQR, 9-20 days]; 72 boys [66%]) included 109 neonates; 51 (47%) had a pre-iNO FiO 2 of 1.0. Neonates with early acute pulmonary hypertension more frequently had a positive iNO response (71% [186 of 262] vs 41% [45 of 109]) and lower mortality (34% [90 of 262] vs 49% [53 of 109]) than those with late acute pulmonary hypertension. Accounting for pretreatment illness factors, greater reduction in FiO 2 with iNO remained associated with lower mortality for neonates with early acute pulmonary hypertension (adjusted odds ratio per FiO 2 reduction of 0.10, 0.74 [95% CI, 0.65-0.84]). For those with late acute pulmonary hypertension, however, only pretreatment illness severity (lower pre-iNO FiO 2 and higher pre-iNO pH), and not positive response to iNO (adjusted odds ratio, 0.47 [95% CI, 0.17-1.30]), was associated with mortality. Conclusions and Relevance In this cohort study of very preterm neonates with acute pulmonary hypertension treated with iNO, responsiveness to iNO was associated with improved outcomes during the first 72 hours of age. The prognostic role of iNO response in acute pulmonary hypertension presenting after 72 hours of age remains unclear. Future studies should investigate the distinct pathophysiological mechanisms associated with late acute pulmonary hypertension in this population.